公开(公告)号：US06770671B2

公开(公告)日：2004-08-03

申请号：US10220724

申请日：2002-09-04

Applicant: Jung Joon Lee ,  Jeong-Hyung Lee ,  Hang Sub Kim ,  Young-Soo Hong ,  Yun Joo Park

Inventor： Jung Joon Lee ,  Jeong-Hyung Lee ,  Hang Sub Kim ,  Young-Soo Hong ,  Yun Joo Park

IPC: A61K3135

CPC classification number: C12R1/66 ,  C07D311/86 ,  C12P17/06

Abstract: Disclosed are a novel compound represented by the following chemical formula (1), useful for the prophylaxis and treatment of angiogenic diseases, its production, and a novel microorganism producing the same. Aspergillus sp. Y80118 isolated from soil was found to produce 7,8-dihydro-1,7-dihydroxy-3-hydroxymethyl-xanthenone-8-carboxylic acid methylester which inhibits VEGF-induced proliferation of HUVEC, angiogenesis in CAM assay, and tumor growth. The novel compound can be effectively used for the medical treatment of anigiogenic diseases, including cancers, rheumatoid arthritis, and diabetic retinopathy.

Abstract translation: 公开了由以下化学式（1）表示的新型化合物，其用于预防和治疗血管生成疾病及其生产，以及生产该新化合物的新型微生物。 曲霉菌 发现从土壤中分离的Y80118产生抑制VEGF诱导的HUVEC增殖，CAM测定中的血管发生和肿瘤生长的7,8-二氢-1,7-二羟基-3-羟甲基 - 呫吨酮-8-羧酸甲酯。 该新型化合物可有效地用于治疗致病性疾病，包括癌症，类风湿性关节炎和糖尿病性视网膜病变。

公开(公告)号：US06632705B1

公开(公告)日：2003-10-14

申请号：US09688297

申请日：2000-10-13

Applicant: Bok-moon Kang ,  Byung-se So ,  Jung-joon Lee

Inventor： Bok-moon Kang ,  Byung-se So ,  Jung-joon Lee

IPC: H01L2144

CPC classification number: G11C5/06 ,  G11C5/025 ,  G11C5/04 ,  H01L23/5386 ,  H01L2924/0002 ,  H01L2924/3011 ,  H05K1/181 ,  H05K2201/09227 ,  H05K2201/097 ,  H05K2201/09781 ,  H05K2201/10159 ,  H05K2203/1572 ,  Y02P70/611 ,  H01L2924/00

Abstract: A memory module and a method of packaging memory devices are provided. The method prepares semiconductor packages of the memory devices, each of which has external pins that include data pins and command signal pins, and mounts the packages on a printed circuit board, on which a first bus, a second bus, and a third bus are formed. The data pins of odd-numbered packages and even-numbered packages connect to the first bus and the second bus, respectively. The control signal pins connect to the third bus. Each package can optionally include dummy pins, where the dummy pins of the even-numbered packages and the odd-numbered packages respectively connect to the first and second buses so that each of the first, second and third buses connects to the same number of external pins. The pin assignment of the even-numbered packages can be different from the pin assignment of the odd-numbered packages to facilitate connections of the buses.

Abstract translation: 提供了一种存储器模块和一种封装存储器件的方法。 该方法制备存储器件的半导体封装，每个存储器件具有包括数据引脚和命令信号引脚的外部引脚，并将封装安装在印刷电路板上，第一总线，第二总线和第三总线 形成。 奇数包和偶数包的数据引脚分别连接到第一总线和第二总线。 控制信号引脚连接到第三总线。 每个封装可以可选地包括虚拟引脚，其中偶数封装的伪引脚和奇数封装分别连接到第一和第二总线，使得第一，第二和第三总线中的每一个连接到相同数量的外部 针脚。 偶数封装的引脚分配可能与奇数封装的引脚分配不同，以方便总线的连接。

公开(公告)号：US6162437A

公开(公告)日：2000-12-19

申请号：US978321

申请日：1997-11-25

Applicant: Kwang-Ho Pyun ,  Inpyo Choi ,  Hyung-Sik Kang ,  Jung-Joon Lee ,  Young-Ho Kim

Inventor： Kwang-Ho Pyun ,  Inpyo Choi ,  Hyung-Sik Kang ,  Jung-Joon Lee ,  Young-Ho Kim

IPC: A61K36/59 ,  A61K35/78

CPC classification number: A61K36/59

Abstract: Method for inhibiting the production of interleukin-6 (hereinafter, referred to as "IL-6") in human body, which comprises administering extracts from a root of Stephania tetrandra S. Moore; and method for treating a patient of an immune disease caused by an overproduction of interleukin-6 by inhibiting the production of interleukin-6, which comprises administering extracts from a root of Stephania tetrandra S. Moore to the patient.

Abstract translation: 抑制人体中白细胞介素-6（以下称为“IL-6”）的产生的方法，其包括施用来自Stephania tetrandra S.Moore的根的提取物; 以及通过抑制白细胞介素-6的产生来治疗由白细胞介素-6过量产生引起的免疫疾病的患者的方法，其包括向患者施用来自Stephania tetrandra S.Moore的根的提取物。

公开(公告)号：US20170239259A1

公开(公告)日：2017-08-24

申请号：US14569201

申请日：2014-12-12

Applicant: Kyeong LEE ,  Mi Sun WON ,  Hwan Mook KIM ,  Song Kyu PARK ,  Kiho LEE ,  Ki Hoon LEE ,  Chang Woo LEE ,  Jung Joon LEE ,  Kyung Sook CHUNG ,  Bo Kyung KIM ,  Yinglan JIN ,  Seung-hee LEE

Inventor： Kyeong LEE ,  Mi Sun WON ,  Hwan Mook KIM ,  Song Kyu PARK ,  Kiho LEE ,  Ki Hoon LEE ,  Chang Woo LEE ,  Jung Joon LEE ,  Kyung Sook CHUNG ,  Bo Kyung KIM ,  Yinglan JIN ,  Seung-hee LEE

IPC: A61K31/5375 ,  A61K31/167 ,  A61K31/196 ,  A61K31/40 ,  A61K31/34 ,  A61K9/08 ,  A61K31/417 ,  A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/24 ,  A61K31/4409

CPC classification number: A61K31/5375 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/167 ,  A61K31/196 ,  A61K31/24 ,  A61K31/34 ,  A61K31/40 ,  A61K31/417 ,  A61K31/4409 ,  C07C233/07 ,  C07C235/28 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C2603/74 ,  C07D295/088

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis.Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

公开(公告)号：US08559241B2

公开(公告)日：2013-10-15

申请号：US13110161

申请日：2011-05-18

Applicant: Sung-Joo Park ,  Jea-Eun Lee ,  Jung-Joon Lee ,  Yang-Ki Kim ,  Kyoung-Sun Kim

Inventor： Sung-Joo Park ,  Jea-Eun Lee ,  Jung-Joon Lee ,  Yang-Ki Kim ,  Kyoung-Sun Kim

IPC: G11C7/10

CPC classification number: G11C7/1078 ,  G11C7/1084 ,  G11C8/06

Abstract: A data receiver includes a first buffer circuit and a second buffer circuit. The first buffer circuit varies a resistance of a data path and a resistance of a reference voltage path based on a plurality of control signals, and adjusts a voltage level of an input data signal and a level of a reference voltage to generate an internal data signal and an internal reference voltage based on the varied resistance of the data path and the varied resistance of the reference voltage path. The second buffer circuit compares the internal data signal with the internal reference voltage to generate a data signal.

Abstract translation: 数据接收机包括第一缓冲电路和第二缓冲电路。 第一缓冲电路基于多个控制信号改变数据路径的电阻和参考电压路径的电阻，并且调整输入数据信号的电压电平和参考电压的电平以产生内部数据信号 以及基于数据路径的变化的电阻和参考电压路径的变化的电阻的内部参考电压。 第二缓冲电路将内部数据信号与内部参考电压进行比较以产生数据信号。

公开(公告)号：US20130202167A1

公开(公告)日：2013-08-08

申请号：US13604389

申请日：2012-09-05

Applicant: Jung-joon LEE

Inventor： Jung-joon LEE

IPC: G06K9/62

CPC classification number: G16B25/00 ,  G16B40/00

Abstract: A method and apparatus for generating a gene expression profile by obtaining data relating to phenotypes and data relating to gene expression from biological samples and statistically analyzing them together.

Abstract translation: 一种通过从生物样品获得与表型有关的数据和与基因表达有关的数据并统一分析它们的方式产生基因表达谱的方法和装置。

公开(公告)号：US07902190B2

公开(公告)日：2011-03-08

申请号：US12442930

申请日：2007-09-27

Applicant: Kyeong Lee ,  Hyun Sun Lee ,  Jung Joon Lee ,  Young Kook Kim ,  Mun-Chual Rho ,  Jeong Hyung Lee ,  Hye-Ran Park ,  Chul-Ho Lee ,  Yongseok Choi

Inventor： Kyeong Lee ,  Hyun Sun Lee ,  Jung Joon Lee ,  Young Kook Kim ,  Mun-Chual Rho ,  Jeong Hyung Lee ,  Hye-Ran Park ,  Chul-Ho Lee ,  Yongseok Choi

IPC: A61K31/535

CPC classification number: C07D209/18 ,  C07D405/12 ,  C07D409/14

Abstract: Disclosed are indole derivatives, a preparation method thereof, and a composition for the prevention and treatment of metabolic diseases, containing the same as an active ingredient. The indole derivatives have inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to effectively control lipid metabolism and energy metabolism, the composition is thus useful in the prevention and treatment of metabolic diseases, such as obesity and diabetes.

Abstract translation: 公开了吲哚衍生物，其制备方法和用于预防和治疗代谢疾病的组合物，其含有活性成分。 吲哚衍生物对DGAT（二酰基甘油酰基转移酶）具有抑制作用，其在脂质代谢过程中引起诸如肥胖症和糖尿病等代谢疾病。 具有有效控制脂质代谢和能量代谢的能力，因此该组合物可用于预防和治疗诸如肥胖症和糖尿病等代谢疾病。

公开(公告)号：US07799605B2

公开(公告)日：2010-09-21

申请号：US11878697

申请日：2007-07-26

Applicant: Sung-Joo Park ,  Kyoung-Sun Kim ,  Jung-Joon Lee ,  Jea-Eun Lee

Inventor： Sung-Joo Park ,  Kyoung-Sun Kim ,  Jung-Joon Lee ,  Jea-Eun Lee

IPC: H01L21/44 ,  H01L23/48

CPC classification number: H05K1/141 ,  H01L23/5385 ,  H01L24/16 ,  H01L24/81 ,  H01L2224/0554 ,  H01L2224/05568 ,  H01L2224/05573 ,  H01L2224/16225 ,  H01L2924/00014 ,  H01L2924/14 ,  H05K1/0268 ,  H05K3/3436 ,  H05K2201/10378 ,  H05K2201/10734 ,  H05K2203/0455 ,  Y02P70/613 ,  H01L2924/00 ,  H01L2224/05599 ,  H01L2224/0555 ,  H01L2224/0556

Abstract: A method of forming an integrated circuit module may include interposing an auxiliary PCB between at least one semiconductor chip and a main PCB, the auxiliary PCB having at least one circuit pattern for electrical connection to one of the semiconductor chip and at least one circuit pattern formed on the main PCB.

Abstract translation: 形成集成电路模块的方法可以包括在至少一个半导体芯片和主PCB之间插入辅助PCB，辅助PCB具有至少一个用于电连接到半导体芯片中的一个的电路图案和形成的至少一个电路图案 在主PCB上。

公开(公告)号：US20100075962A1

公开(公告)日：2010-03-25

申请号：US12442930

申请日：2007-09-27

Applicant: Kyeong Lee ,  Hyun Sun Lee ,  Jung Joon Lee ,  Young Kook Kim ,  Mun-Chual Roh ,  Jeong Hyung Lee ,  Hye-Ran Park ,  Chul-Ho Lee ,  Yongseok Choi

Inventor： Kyeong Lee ,  Hyun Sun Lee ,  Jung Joon Lee ,  Young Kook Kim ,  Mun-Chual Roh ,  Jeong Hyung Lee ,  Hye-Ran Park ,  Chul-Ho Lee ,  Yongseok Choi

IPC: A61K31/5377 ,  C07D209/04 ,  C07D401/02 ,  C07D413/02 ,  A61K31/405 ,  A61K31/454 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D209/18 ,  C07D405/12 ,  C07D409/14

Abstract: Disclosed are indole derivatives a preparation method thereof, and a composition for the prevention and treatment of metabolic diseases, containing the same as an active ingredient. The indole derivatives have inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to effectively control lipid metabolism and energy metabolism, the composition is thus useful in the prevention and treatment of metabolic diseases, such as obesity and diabetes.

Abstract translation: 公开了吲哚衍生物及其制备方法，以及用于预防和治疗代谢疾病的组合物，其含有活性成分。 吲哚衍生物对DGAT（二酰基甘油酰基转移酶）具有抑制作用，其在脂质代谢过程中引起诸如肥胖症和糖尿病等代谢疾病。 具有有效控制脂质代谢和能量代谢的能力，因此该组合物可用于预防和治疗诸如肥胖症和糖尿病的代谢疾病。

公开(公告)号：US20080248024A1

公开(公告)日：2008-10-09

申请号：US12039640

申请日：2008-02-28

Applicant: Jung Joon Lee ,  Jeong-Hyung Lee ,  Kyeong Lee ,  Young-Soo Hong ,  Xuejun Jin

Inventor： Jung Joon Lee ,  Jeong-Hyung Lee ,  Kyeong Lee ,  Young-Soo Hong ,  Xuejun Jin

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/70 ,  G01N33/53 ,  A61P9/00 ,  A61P29/00 ,  C12Q1/68 ,  A61K38/02

CPC classification number: C07K16/18 ,  A61K38/1709 ,  C12N15/113 ,  C12N2310/14 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57446 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2510/00 ,  G01N2800/00

Abstract: The present invention relates to a use of ZFP91 based on the functions of ZFP91 (Zinc Finger Protein 91) and the interaction of ZFP91 with NF-κB (Nuclear factor kappa B) signal transduction pathway proteins, more precisely a method to inhibit the activation of NF-κB alternative pathway by regulating ZFP91 activation, to inhibit tumor growth by inhibiting the transcription factor HIF-1 (hypoxia inducible factor-1) activation, to inhibit cancer malignancy by inhibiting angiogenesis, or reversely a method to increase the activation of NF-κB alternative pathway or to increase angiogenesis by increasing activation of HIF-1. The method of regulating ZFP91 activation of the present invention can increase or reduce HIF-1α stability by increasing or reducing the activation of NF-κB alternative pathway, so that it can be effectively used for the development of an anticancer agent, a therapeutic agent for arthritis, a therapeutic agent for ulcerative colitis, an anti-inflammatory agent and an angiogenesis inducer.

Abstract translation: 本发明涉及基于ZFP91（锌指蛋白91）的功能和ZFP91与NF-κB（核因子κB）信号转导途径蛋白的相互作用的ZFP91的应用，更准确地说是抑制活化的方法 NF-κB通过调节ZFP91激活，通过抑制转录因子HIF-1（缺氧诱导因子-1）激活抑制肿瘤生长，通过抑制血管生成来抑制癌症恶性，或反向增加NF- kappaB替代途径或通过增加HIF-1的活化来增加血管生成。 调节本发明ZFP91活化的方法可以通过增加或减少NF-κB替代途径的活化来增加或降低HIF-1α的稳定性，从而可以有效地用于开发抗癌剂，治疗剂 关节炎，溃疡性结肠炎的治疗剂，抗炎剂和血管发生诱导剂。